• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Oral TXA For Heavy Menstrual Bleeding Increase Thromboembolic Risk?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Oral tranexamic acid (TXA) is used to manage heavy menstrual bleeding
    • In Denmark, oral TXA is used to manage acute bleeding, with levonorgestrel-releasing intrauterine system used for long-term management
  • Data on thromboembolic risks of oral TXA are limited
  • Meaidi et al. (EClinicalMedicine, 2021) assessed the association between oral TXA and the risk for venous thromboembolism and arterial thrombosis

METHODS:

  • Danish Nationwide historical prospective cohort (1996 to 2017)
  • Participants
    • 15 to 49 years
    • Exclusions included: History of thromboembolism | Anticoagulation therapy | Thrombophilia | Cancer | Hypertension | Diabetes | Liver Disease
  • Exposure
    • Use of oral TXA, as identified through filled prescriptions
  • Study design
  • Women followed until: End of the study period | Turned 50 years | Emigrated from country | Death | Experienced one of the exclusion criteria
  • Primary outcomes
    • Venous thromboembolism (DVT or PE)  
    • Arterial thrombosis (MI or stroke)

RESULTS:

  • 2.0 million women followed | 13.8 million person-years
    • Women who filled TXA prescriptions: 3.2%
  • Incidence of primary outcome
    • Venous thromboembolisms: 3,392 cases
    • Arterial thromboses: 4,198 cases
  • Age-adjusted incidence rate of venous thromboembolism
    • TXA: 11.8 (95% CI, 4.6 to 30.2) per 10,000 person-years
    • Non-users: 2.5 (95% CI, 2.4 to 2.6) per 10,000 person-years
    • Adjusted incidence rate ratio: 4.0 (95% CI, 1.8 to 8.8)
    • Number needed to harm: 1 extra venous thromboembolism was diagnosed for every 78,549 women using oral tranexamic acid for five days
  • Age-adjusted incidence rate of arterial thrombosis
    • TXA: 3.4 (95% CI, 1.1 to 10.7) per 10,000 person-years
    • Non-users: 3.0 (95% CI, 2.9 to 3.1) per 10,000 person-years
    • Adjusted incidence rate ratio: 1.3 (95% CI 0.4 to 4.2)

CONCLUSION:

  • Compares to non-use, the use of TXA was associated with a 4-fold increase in the incidence of venous thromboembolism but number needed to harm was very high
  • There was no significant link between TXA and incidence of arterial thrombosis
  • Limitations include lack of adjustment for BMI and smoking
  • The authors state

Despite the above-mentioned limitations, the study clearly demonstrates that in a population of healthy women, venous thromboembolism and arterial thrombosis are maximally very rare adverse events of temporarily, short-lasting use of oral tranexamic acid, which is comparable with the risk attached to use of combined oral contraception

Learn More – Primary Sources:

Oral tranexamic acid and thrombosis risk in women

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

How does TXA Measure Up as a Treatment for Menorrhagia?
Meta-Analysis: Is There an Association Between TXA and Increased Risk for Thromboembolic Events?
Results From the Landmark Trial on Tranexamic Acid for Postpartum Hemorrhage

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site